Key result
Hyperglycemia, lipid gene variants, and arterial oxidative modification drive accelerated vascular disease in diabetes.
Answers are grounded in this paper and cite their sources.
Most patients with diabetes die from macrovascular complications. Little is known about the pathogenesis of diabetic vascular disease, but recent advances in molecular genetics and oxidation chemistry provide clues to the mystery of diabetes and atherosclerosis. Genetic variants of well-known proteins such as lipoprotein lipase and apolipoprotein E are common. These proteins are suitable candidates for mediating diabetic vascular risk because their variants can produce hypertriglyceridemia, a risk factor for atherosclerosis in diabetes. However, mutations could have different effects on lipoprotein flux across arteries depending on whether expression is dominant in the vascular space or the vascular wall. Lipoproteins retained in the arterial wall are subject to oxidative modification, which could be dependent on glycoxidation, the enzyme myeloperoxidase, or reactive nitrogen species derived from nitric oxide. Accelerated vascular disease in diabetes is likely the result of complex interactions between metabolic derangements such as hyperglycemia, mutations in genes controlling lipid metabolism, and antioxidant defense mechanisms.
No takes yet. Share an insight, caveat, or question.
Semenkovich et al. (1997) conducted a review in Diabetes and atherosclerosis (diabetic vascular disease). Genetic variants in lipid metabolism (lipoprotein lipase, apolipoprotein E) and oxidative modification pathways was evaluated on Pathogenesis of accelerated vascular disease and atherosclerosis in diabetes. Complex interactions among hyperglycemia, lipid metabolism gene variants (LPL, apoE), and arterial oxidative modification likely drive accelerated vascular disease in diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: